Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
Date:4/30/2009

2008 and to $16.3 million and $14.7 million, respectively, in the first quarter of 2008, reflecting a reduction in expenses of 17.4% in a single quarter and 61.2% as compared to the first quarter in 2008, both on an adjusted basis. - Selling, general and administrative expenses were $19.6 million, and as adjusted to exclude non-cash stock-based compensation expenses, non-recurring termination related costs, certain litigation costs and non-recurring financing fees were $17.0 million. These results compare to $21.4 million and $19.0 million, respectively, in the fourth quarter of 2008 and to $27.8 million and $23.3 million, respectively, in the first quarter of 2008. - GAAP net income and net income per share from continuing operations for the quarter were $12.4 million and $0.14, respectively, compared to a net loss of ($15.7) million and ($0.19) for the first quarter of 2008. The increase in net income of $28.1 million is due primarily to an increase in license revenue as a result of the one-time payment of $25.0 million received relating to our amended and restated Distribution and License Agreement with Baxter as announced on March 31, 2009, a $10.5 million decrease in research and development costs deriving primarily from the completion or termination of various of our human clinical trial activities and from certain cost reduction initiatives that were implemented during 2008, a decrease in general and administrative costs deriving primarily from certain cost reduction initiatives that were implemented during 2008, and a lower interest rate incurred on our senior floating rate notes. These factors were partially offset by a reduction of $12.3 million in royalty revenue derived from Boston Scientific Corporation's ("BSC") sales of paclitaxel-eluting
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Angiotech announces date of annual general meeting of shareholders
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
3. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
4. Angiotech announces positive results from Bio-Seal(TM) clinical study
5. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals announces time change of conference call and webcast
8. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
9. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
10. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015   Intrexon Corporation (NYSE: ... quarter 2015 financial results after the market closes on ... call that day at 5:30 PM ET to discuss ... The conference call may be accessed by dialing ... join the "Intrexon Conference Call."  Participants may also access ...
(Date:5/4/2015)... Wheaton, Illinois (PRWEB) May 04, 2015 ... treatment options for patients with arm and hand ... rehabilitation exoskeleton at its Oakbrook Terrace network site. ... foundation, the Armeo®Spring is a highly-regarded treatment option ... In acquiring the Armeo®Spring, Marianjoy becomes one of ...
(Date:5/1/2015)... May 01, 2015 OncoTAb, Inc., ... Charlotte) spin-out company, announced that Pinku Mukherjee, Ph.D. has ... UNC Board of Governors’ highest faculty honor. Mukherjee received ... welfare , for her innovative research and development of ... Award represents a crowning moment in my scientific career,” ...
(Date:5/1/2015)... 2015 Pfenex Inc. (NYSE MKT: PFNX), ... of biosimilar therapeutics including high value and difficult ... quarter 2015 financial results will be released on ... market. At 8:30 am Eastern Time, Pfenex management will ... results and provide a business update. A press release ...
Breaking Biology Technology:Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2
... Novavax, Inc. (Nasdaq:,NVAX) today announced financial results for the first ... loss per share) for the first,quarter of 2008 compared to ... the first quarter of 2007. Total cash and short-term investments,as ... million as of,December 31, 2007. The cash burn for the ...
... China-Biotics,Inc. (OTC Bulletin Board: CHBT) ("China-Biotics," "the Company"), ... development,marketing and distribution of probiotics products, today announced ... at Qing Pu, Shanghai., "The new plant ... cornerstone of our,growth strategy. We have put over ...
... Netherlands, May 9 /PRNewswire/,-- University Hospitals Case ... the Companies have the intention to found ... and medical imaging,services to clients that are ... in world wide studies., University Hospitals ...
Cached Biology Technology:Novavax Reports First Quarter 2008 Financial Results 2Novavax Reports First Quarter 2008 Financial Results 3Novavax Reports First Quarter 2008 Financial Results 4Novavax Reports First Quarter 2008 Financial Results 5Novavax Reports First Quarter 2008 Financial Results 6Novavax Reports First Quarter 2008 Financial Results 7Novavax Reports First Quarter 2008 Financial Results 8China-Biotics, Inc. Completes Foundation for Its New Plant 2University Hospitals Case Medical Center, Cleveland, USA and Cardialysis BV, Rotterdam, the Netherlands Enter Strategic Alliance to Found Cardialysis Cleveland 2University Hospitals Case Medical Center, Cleveland, USA and Cardialysis BV, Rotterdam, the Netherlands Enter Strategic Alliance to Found Cardialysis Cleveland 3
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... smart wallets is underway to early access pre-order customers. ... includes usage at retail outlets including Walmart, Target, AT&T, ... report Wocket was accepted at all outlets and very ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... the Electronic Nose, which has the potential to diagnose ... grant from Grand Challenges Canada and the Bill & ... testing of this ground-breaking technology. The ... able to detect TB immediately and non-invasively from the ...
... family of compounds that includes one of the most ... treatments. But the difficulty producing these complex molecules in ... family for further drug leads. Now, a group of ... step toward the goal of synthetically producing Taxol and ...
... name "Sleeping Beauty" has helped to unlock vital clues ... A study published today used the Sleeping Beauty transposon ... drive colorectal cancer, identifying many more than previously thought. ... human cancer, which provides strong evidence that they are ...
Cached Biology News:Creating an 'electronic nose' to sniff out tuberculosis from a patient's breath 2Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 2Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 3Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 4Researchers discover genes involved in colorectal cancer 2
... Incubator/Shaker HT is designed for ... Incubator/Shaker HT is ideal for ... and primer extension assays. iEMS ... a one-cabinet model, allowing the ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
...
... PTOs are internucleotide modifications, where ... is replaced by a sulphur atom. This ... PTOs are available as Full-PTOs ... Oligonucleotides with thio-caps Several ...
Biology Products: